Scienmag

JANUARY 14, 2021

14, 2021) – Researchers at Baylor College of Medicine have discovered how therapeutics targeting RNA splicing can activate antiviral immune pathways in triple negative breast cancers (TNBC) to trigger tumor cell death and signal the body’s immune response. HOUSTON – (Jan.

Immune Response 41

Immune Response RNA Medicine Research 41

pharmaphorum

SEPTEMBER 23, 2021

AstraZeneca has joined the ranks of big pharma companies bolting on RNA-based technology platforms in the wake of the stellar success of mRNA vaccines for COVID-19. There has been a flurry of other licensing and M&A deals in the RNA space since the start of the pandemic, headlined by Sanofi’s $3.2

RNA 52

RNA Immune Response Vaccination Vaccine 52

STAT News

NOVEMBER 24, 2022

An experimental influenza vaccine developed using messenger RNA technology appears capable of inducing what should be a protective immune response against all known subtypes of flu, at least in animals. If the work is translated into humans it could turn out to be a version of a long-sought universal vaccine.

Vaccination 138

Vaccination Vaccine RNA Immune Response 138

The Pharma Data

MAY 17, 2021

The interim results from the phase 2 trial on the vaccine, published today, on the contrary, showed a “ strong neutralizing antibody response” ? The companies also noted a high immune response after a single dose of the shot in patients with prior infection, indicating, they said, strong booster potential for the jab. “

Immune Response 52

Immune Response Vaccination Vaccine Antibody 52

The Pharma Data

AUGUST 16, 2021

Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV. “In Induction of innate immunity was investigated via specific cytokine markers.

Immune Response 52

Immune Response Vaccination Vaccine Antibody 52

pharmaphorum

AUGUST 31, 2021

Just a few months after breaking cover with its new take on RNA therapeutics, Laronde has raised an impressive $440 million in second-round financing backed by Flagship Pioneering – which was behind the founding of mRNA specialist Moderna. The post ‘Endless RNA’ startup Laronde raises $440m to fuel pipeline appeared first on.

RNA 52

RNA Protein Immune Response Medicine 52

The Pharma Data

SEPTEMBER 10, 2020

Pfizer-BioNTech announced Wednesday that preliminary preclinical data from mouse and macaque monkey models showed a strong immune response from its mRNA COVID-19 vaccine. . Photo by Md. Tareq Aziz Touhid.

Immune Response 52

Immune Response Vaccination Vaccine RNA 52

Pharmaceutical Technology

JUNE 30, 2022

The vaccine leverages self-amplifying RNA (saRNA), which can replicate itself after administration and could be effective at very low doses. This technology can stimulate an immune response with a dose up to 20 times lower than current vaccines, which enhances safety, lowers costs, and increases production speed. .

Vaccination 162

Vaccination Vaccine Clinical Trials Clinical Trials 162

Pharmaceutical Technology

NOVEMBER 22, 2022

Messenger RNA vaccines contain nucleic acids that code for a specific protein, or target antigen, related to a virus or disease. When an mRNA vaccine is administered, a patient’s body produces that protein to prompt a desired immune response. million in funding to support this work.

Manufacturing 130

Manufacturing RNA Vaccination Vaccine 130

Pharmaceutical Technology

JUNE 8, 2023

The company’s samRNA vector is based on a synthetic RNA molecule derived from a wild-type Venezuelan Equine Encephalitis Virus (VEEV) replicon with the goal of extending the duration and magnitude of immunogen expression to drive potent and durable immune responses.

Vaccination 130

Vaccination Vaccine Clinical Trials Clinical Trials 130

Drug Discovery World

NOVEMBER 17, 2022

The study is the first to use transcriptomics as a blood test to measure RNA levels in patients with long-term Lyme disease. . As part of the study, RNA sequencing was conducted using blood samples from 152 patients with symptoms of post-treatment Lyme disease to measure their immune response. .

Genetics 52

Genetics RNA Immune Response Gene 52

Camargo

JULY 27, 2021

As with any standard drug treatment, gene therapies carry potential risks, including adverse events, unexpected gene modification (activation or inactivation), undesired immune responses, or complications with the genetic material. Route of Administration Considerations.

Gene Therapy 238

Gene Therapy Gene Gene Editing Genetics 238

Delveinsight

SEPTEMBER 23, 2021

858 Therapeutics closes USD 60 Million series A round to drug RNA modulation. Now, they are ready for their next venture, which is launching RNA biotech 858 Therapeutics with a USD 60 million Series A fundraising. 858’s drug candidates include proteins, which regulate RNA and immune response.

RNA 61

RNA Gene Therapy Gene Protein 61

Pharmaceutical Technology

FEBRUARY 15, 2023

The non-structural proteins NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5 are involved in viral RNA replication and dampening of the host innate immune response. The structural proteins include the capsid, pre-membrane/membrane proteins and envelope (E) proteins.

Vaccination 130

Vaccination Vaccine Protein Antibody 130

Drug Discovery World

FEBRUARY 13, 2023

SB: Transcriptomics is the study of genomic RNA transcripts in a biological system. RNA transcript expression levels can provide insight into underlying biology – eg. In terms of technical process, traditional RNA sequencing was a very laborious process that could take several weeks and was prone to errors. SB: Certainly.

Drugs 52

Drugs RNA Gene Gene Expression 52

Scienmag

MARCH 17, 2021

How one long noncoding RNA could help improve outcomes in bone marrow and solid organ transplantation A long noncoding RNA whose function was previously unknown turns out to play a vital role in mobilizing the immune response following a bone marrow transplant or solid organ transplantation.

RNA 61

RNA Immune Response Medicine 61

pharmaphorum

JANUARY 5, 2022

A COVID-19 vaccine that could work against multiple variants of the coronavirus – developed by US biotech Gritstone bio – has generated encouraging immune response data in its first clinical trial.

Vaccination 126

Vaccination Vaccine Protein Immune Response 126

Drug Discovery World

NOVEMBER 30, 2022

Exosomes are emerging as an effective, non-viral chassis for genetic medicines, as they are non-toxic, efficient at delivering RNA cargoes into cells and able to do so without eliciting an immune response. .

RNA 52

RNA Immune Response Production Gene 52

pharmaphorum

JULY 6, 2021

PCR tests screen for the presence of viral RNA from a swab, detecting whether an individual is currently infected. Because antibody tests detect neutralising antibodies rather than monitoring for an active infection, a positive result can prove that the immune system has developed the capacity to defeat a future infection.

Antibody 111

Antibody Immune Response Protein Vaccination 111

The Pharma Data

OCTOBER 25, 2020

German drugmaker CureVac said preclinical studies of its COVID-19 vaccine candidate, CVnCoV, showed the vaccination prompted a successful immune response. The messenger RNA-based vaccine, which is designed to block replication of the coronavirus, was shown to induce neutralizing antibodies and activate T-cells in hamsters and mice.

Vaccination 52

Vaccination Vaccine Immune Response Clinical Trials 52

Pharmaceutical Technology

FEBRUARY 3, 2023

Now, the HIV research community is setting its sights on vaccines that are in earlier stages of development, based on new approaches like messenger RNA (mRNA) -based vaccines or those using human cytomegalovirus (HCMV) vectors.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

pharmaphorum

JANUARY 10, 2023

Since then, the two partners have developed multiple AI-based applications including a platform for selecting neoantigens for use in individualised cancer vaccines and an early warning system for high risk SARS-CoV-2 variants based on how well they can evade the immune system and their transmissibility.

Clinical Trials 116

Clinical Trials Clinical Trials Vaccination Vaccine 116

The Pharma Data

MARCH 8, 2022

Proteins of SARS-CoV-2 can alter viral ribonucleic acids in a way, that they become indistinguishable from endogenous RNA. Camouflage protects virus from immune system. For example, viral RNAs are masked by the addition of a methyl group. “A robust, early type I IFN production is key to clearing SARS-CoV-2 infection.

Immune Response 52

Immune Response RNA Protein Genetics 52

Drug Discovery World

MAY 18, 2023

This Phase I trial will test the experimental vaccine, known as H1ssF-3928 mRNA-LNP, for safety and its ability to induce an immune response. Both vaccines use a specific portion of a flu protein, hemagglutinin (HA), to induce a broad immune response against influenza.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

pharmaphorum

SEPTEMBER 14, 2021

Rome Therapeutics – which officially launched last year – has made shining a light on the so-called ‘dark genome’ its mission, and has already discovered that repeats can play a critical role in human health, such as by switching on the innate immune response under stress.

DNA 52

DNA Drugs RNA Immune Response 52

Drug Discovery World

FEBRUARY 6, 2023

We use MA plots, heatmaps, pathway maps, and trend plots of clusters (clusters for features with correlated response) as shown in Figure 2 but also UpSet plots, advanced Venn diagrams, to summarise overlap in differential features across multiple timepoints and study arms.

Big Data 52

Big Data RNA Clinical Trials Clinical Trials 52

Delveinsight

AUGUST 26, 2021

Shape’s RNA editing technologies can modify the RNA sequence, which makes the body’s protein building blocks. This system is designed to deliver RNA editing technology or other payloads directly to particular body areas, such as the nervous system or muscle.

Gene Therapy 98

Gene Therapy Vaccination Vaccine RNA 98

Drug Discovery World

JUNE 27, 2023

Scientists from Japan have identified regulator CD69, which controls the differentiation of CD8+ T cells within tumour-draining lymph nodes, thereby regulating anti-tumour immunity. Future cancer treatment based on antibodies against CD69 could enhance anti-tumour immune responses of CD8+ T cells and lead to more efficient cancer therapies.

Antibody 52

Antibody RNA Immune Response Scientist 52

Drug Discovery World

APRIL 16, 2023

Vaccine strategies over the last 25 years attempted to induce immune responses against tumour-associated antigens that are not absolutely specific to the tumour,” said presenting author Jeffrey Weber, Deputy Director of the NYU Langone Perlmutter Cancer Center and Laura and Isaac Perlmutter Professor of Oncology at NYU Grossman School of Medicine.

Vaccination 52

Vaccination Vaccine Immune Response Gene Expression 52

Drug Discovery World

JULY 26, 2022

Pharmaceutical company BioNTech will deliver the 2022 César Milstein Lecture on 26 July with a focus on how messenger RNA (mRNA) technology can be used within vaccines for cancer and Covid-19. . The lecture will be delivered in two halves by U?ur ahin and Özlem Türeci, co-founders of BioNtech. .

Vaccination 52

Vaccination Vaccine Immune Response Antibody 52

pharmaphorum

OCTOBER 2, 2020

NEO, which is designed to be produced on-demand according to the neoantigen profile of an individual patient and produces an immune response that attacks the tumour. Frame Therapeutics has also begun work on neoantigen-based cancer vaccines based on RNA technology. The deal focuses on Vaccibody’s investigational product VB10.NEO,

Vaccination 59

Vaccination Vaccine Drugs Immune Response 59

Worldwide Clinical Trials

JUNE 15, 2022

Further, some patients are still hesitant to go into the clinic, and the prevalence of misinformation from the pandemic has led to greater concerns about therapies like gene therapies and the impact they fear it will have on their RNA/DNA.

Gene Therapy 130

Gene Therapy Gene Clinical Trials Clinical Trials 130

pharmaphorum

FEBRUARY 9, 2021

InteRNA is focusing on the development of gene-silencing drugs based on microRNA, naturally occurring, non-coding strands of RNA that are thought to regulate gene expression in cells. The major difference between siRNAs and microRNAs is that the former are very specific to one messenger RNA target, while the latter can have multiple targets.

Trials 59

Trials Gene Silencing RNA Clinical Trials 59

Drug Discovery World

APRIL 12, 2023

Upon administration into the body, the algorithmically derived and RNA-encoded neoantigen sequences are endogenously translated and undergo natural cellular antigen processing and presentation, a key step in adaptive immunity.

Vaccination 52

Vaccination Vaccine RNA Immune Response 52

The Pharma Data

DECEMBER 14, 2020

Supported by promising phase 1 data, CureVac announced Monday that it has enrolled the first participant in the pivotal phase 2b/3 study of its messenger-RNA based coronavirus vaccine, CVnCoV. The company announced positive phase 1 trial results in November that demonstrated its candidate elicited immune responses and was well-tolerated.

Vaccination 52

Vaccination Vaccine Trials RNA 52

pharmaphorum

OCTOBER 12, 2022

The payload, Del Bourgo tell us, is the therapeutic DNA or RNA sequence that will cure or fix damaged cells. Similar to how we injected mRNA into people to trigger an immune response and train their immune system against COVID-19, genomic medicine repairs cellular or molecular mechanisms that are dysfunctional and cause disease.”.

Genome 105

Genome Genomics Medicine Development 105

pharmaphorum

OCTOBER 6, 2020

The vaccine is based on different technology from AZ’s rival: while AZ’s uses a weakened and genetically modified cold virus to prime the immune system, BNT162b2 is based on a string of RNA.

Vaccination 59

Vaccination Vaccine RNA Immune Response 59